Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 10/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.66 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.66 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29537895 | 1.00 | FTO (0.66) | FTOMAPTMEN1KMT2AHPGD | |
| SCHEMBL15059064 | 0.91 | FTO (0.70) | FTOMAPTMEN1KMT2AHPGD | |
| SCHEMBL29995323 | 0.91 | FTO (0.70) | FTOMAPTMEN1KMT2AHPGD | |
| SCHEMBL20833 | 0.89 | FTO (0.67) | FTOMAPTMEN1KMT2AHPGD | |
| SCHEMBL29613006 | 0.89 | FTO (0.67) | FTOMAPTMEN1KMT2AHPGD | |
| SCHEMBL29353864 | 0.89 | FTO (0.67) | FTOMAPTMEN1KMT2AHPGD | |
| Water SCHEMBL25244476 | 0.88 | FTO (0.66) | FTOMAPTMEN1KMT2AHPGD | |
| SCHEMBL14604845 | 0.88 | FTO (0.66) | FTOMAPTMEN1KMT2AHPGD | |
| Ammonia Solution, Strong SCHEMBL29083295 | 0.88 | FTO (0.66) | FTOMAPTMEN1KMT2AHPGD | |
| SCHEMBL27907992 | 0.88 | FTO (0.66) | FTOMAPTMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123836-A1 | IMMUNE-ACTIVATING COMPLEXES | DYNAMIC CELL THERAPIES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| WO-2024123835-A1 | ENGINEERED SWITCHES FOR IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF | DYNAMIC CELL THERAPIES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| WO-2024123836-A1 | IMMUNE-ACTIVATING COMPLEXES | DYNAMIC CELL THERAPIES, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123835-A1 | ENGINEERED SWITCHES FOR IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF | DYNAMIC CELL THERAPIES, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20140023592-A1 | SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS | RWTH AACHEN (DE) | 2014-01-23 | — | — | US | disclosed |
| EP-2587263-A1 | Self coupling recombinant antibody fusion proteins | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2013-05-01 | — | — | EP | disclosed |
| US-20110014196-A1 | Drug Transfer into Living Cells | COVALYS BIOSCIENCES AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-20100183516-A1 | SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-2171456-A2 | SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009043899-A1 | DRUG TRANSFER INTO LIVING CELLS | COVALYS BIOSCIENCES AG (CH) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009013359-A2 | SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS | FRAUNHOFER GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014196-A1 | Drug Transfer into Living Cells | TSPO, MPI, ABCB1 | FTO 1922/4885MAPT 237/4885MEN1 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.